We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Trader_3,
Thanks for the link !
Worth re-playing this also , from a US listing perspective, ex pogue on a d v f n :
.."Interesting commentary on ORPH 6min 30 secs in is the beginning
hTTps://shows.acast.com/uk-investor-magazine-flash-briefing/episodes/us-elections-impact-on-uk-equites-and-is-it-more-important-t
One point brought up was the comparison between ORPH and our partner in antibody testing Quotient Sciences, who provide pharma services as well, got me seeking the sedatives again hTTps://www.quotientsciences.com/
$32m revenue however made a loss, Market Capital $665m (its listed on NASDAQ).
We are currently circa £120m.
We need to have a word with CF to get his passport out and get over to NY..."
ATB
All good, but as usual, no mention of the non-core assets basically being a potential bogof.
Couldn’t have put it better me self
Value the Markets Article 28 OCT 2020 | Galina Mikova
Open Orphan (LSE:ORPH)
The outlook for pharmaceutical services company Open Orphan (LSE:ORPH) has never looked stronger following the announcement of a Covid-19 vaccination contract with the UK Government worth up to £40 million.
The first part of the contract will see the firm’s subsidiary hVIVO develop a Covid-19 human challenge study model. This will include manufacturing the challenge virus and the first-in-human characterization study for the virus, with completion scheduled for May next year.
In the six months leading up to June, the Dublin-based firm reported an operating loss of £5 million. However, the second half of 2020 has seen momentum grow as the company has begun to enjoy the full financial benefits of its hVIVO acquisition and its strong pipeline of contracted work.
In its half-year results, Open Orphan said it was on track to be operationally profitable in the fourth quarter of 2020. And following the announcement last week that the UK Government had paid three slot reservation payments to the firm at £2.5 million apiece for full Covid-19 human challenge study vaccine trials to be held next year, things are looking even brighter.
Each of these studies has a potential market value of between £8-10 million. This means that the total value of the UK Government contract could reach up to £40 million when an initial £10 million payment is taken into account.....
......The company has secured funding for the entirety of the study, which will be sponsored by Imperial College London and conducted by hVIVO at The Royal Free Hospital’s specialist research unit in London, under the scrutiny of highly trained scientists and medics.
But this is not the only good news for shareholders and investors.
This year has also seen Open Orphan announce the signing of larger, more profitable contracts with both large pharma and leading vaccine developers globally....
.....Looking ahead, the outlook for Open Orphan looks extremely positive, fueled by the potential for the business as it enters a period of significant spending on vaccines and antivirals by both governments and pharma companies around the world.
The results from the human challenge study could clearly have a tremendous impact on Open Orphan’s future growth. As encouraging as the number of contracts the company has secured is, the upcoming months are likely to give investors a much better idea on the company’s earnings prospects. For now, Open Orphan’s valuation and substantial portfolio are two solid reasons to look at buying this stock.
https://www.valuethemarkets.com/2020/10/28/analysis-strong-outlook-for-open-orphan-on-uk-government-contract-and-wider-portfolio-progress/
Glad to see someone else agrees with me!